Navigation Links
GEN reports on strategies to overcome blood-brain barrier
Date:2/5/2009

New Rochelle, NY, February 5, 2009The blood-brain barrier (BBB) remains a major obstacle to the successful delivery of drugs to treat central nervous system (CNS) disorders, reports Genetic Engineering and Biotechnology News (GEN). Researchers are exploring a variety of approaches to preserve the ability of the BBB to block harmful and toxic substances from entering the brain and to permit the passage of effective medicines for the treatment of CNS diseases, according to the February 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2778).

"The blood-brain barrier issue probably serves as the most significant roadblock to the treatment of central nervous system diseases," says John Sterling, Editor in Chief of GEN. "The key challenge is to treat people suffering from CNS disorders while trying to stay true to the physician's oath, 'First do no harm'."

One technology for enabling active transport of small molecule drugs across the BBB involves targeting endogenous nutrient transporters. These transporters are members of the solute carrier (SLC) transporter superfamily. Transport of small molecules across the BBB by these membrane proteins is known as carrier-mediated transport (CMT).

In order to design drugs that utilize CMT to cross the BBB, researchers modify their chemical structures so that they resemble nutrients that are transported across the BBB by specific SLCs. The prototypical drug that uses this strategy (which was developed long before mechanisms of CMT were known) is L-DOPA, the major current drug for Parkinson's disease. L-DOPA is used to replace dopamine that is lost due to degeneration of dopaminergic neurons in the substantia nigra of the brain.

Another major system that is used in normal mammalian physiology to enable needed molecules to cross the BBB is receptor-mediated transport (RMT). The brain uses RMT to transport proteins, peptides, and lipoproteins that are needed for brain function across the BBB. Examples of biomolecules that are transported into the brain via RMT include insulin, insulin-like growth factor (IGF), leptin, transferrin, and low-density lipoprotein (LDL).

In RMT, molecules in the circulation may bind to specific receptors on the luminal surface of brain capillaries (i.e., the surface that interfaces with the bloodstream). Upon binding, the receptor-ligand complex is internalized into the endothelial cell by a process called receptor-mediated endocytosis. The ligand may then be transported across the abluminal membrane of the endothelial cell (i.e., the membrane that interfaces with brain tissue) into the brain. This whole process is called receptor-mediated transcytosis.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert

Related biology news :

1. GEN reports on growing reliance on microfluidics technology
2. Cytori reports benefit of adipose-derived regenerative cells in spinal disc model
3. GEN reports growing focus on PI3-kinase pathway in cancer research
4. Genetic Engineering & Biotechnology News reports on the trend toward predictive toxicogenomics
5. Orchid Cellmark Reports Third Quarter 2008 Financial Results
6. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
7. Synaptics Reports Record Results for First Quarter of Fiscal 2009
8. GEN reports on novel tools for deciphering biological networks
9. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
10. LSUHSC research reports new method to protect brain cells from diseases like Alzheimers
11. Communication Intelligence Corporation Reports Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/4/2017)... 2017  For the thousands of attendees at this year,s International Consumer ... health and biometric measurement devices and services, will be featuring its new ... in A&D Medical,s special CES Exhibit Suite , the new upper ... the company,s WellnessConnected product platform.  ... ...
(Date:1/3/2017)... Jan. 3, 2017 Onitor, provider of digital ... Onitor Track, an innovative biometric data-driven program designed to ... month at the 2017 Consumer Electronics Show (CES) in ... In the U.S., the World Health Organization (WHO), have ... of adults who are overweight or obese. WHO also ...
(Date:12/22/2016)... , December 22, 2016 SuperCom ... of secure solutions for the e-Government, Public Safety, HealthCare, and Finance ... of SuperCom, has been selected to implement and deploy a community-based ... Northern California , further expanding its presence in ... This ...
Breaking Biology News(10 mins):
(Date:1/16/2017)... LOUISVILLE, Ky. , Jan. 16, 2017  Eurofins ... service, which will allow more customers to receive their ... price premium or compromise in quality found with other ... the United States at no additional ... variety of routine genetic studies, including DNA sequencing, genotyping, ...
(Date:1/13/2017)... Research and Markets has announced the addition of the "Global Biopolymers ... ... of 16.83% during the period 2017-2021. The report covers ... for 2017-2021. To calculate the market size, the report considers the revenue ... includes a a discussion of the key vendors operating in this market. ...
(Date:1/12/2017)... ... January 12, 2017 , ... ... A SUCCESS , VTI, Vertebral Technologies, Inc., announces the successful outcome of ... device. Since September 2016, VTI (Vertebral Technologies, Inc.) has partnered with Mexico-based ...
(Date:1/12/2017)... , ... January 12, 2017 , ... ... targeted treatments, 26-year-old Lisa Rosendahl’s doctors gave her only a few months to ... new drug combination that has stabilized Rosendahl’s disease and increased both the quantity ...
Breaking Biology Technology: